Drug class in one race
JAK drugs for Atopic Dermatitis
4 tracked JAK drugs in the Atopic Dermatitis race. The class explanation lives on the JAK page; the full indication pipeline across every mechanism is on the Atopic Dermatitis page.
1 approved / phase 42 Phase 31 Phase 2
Head-to-head evidence: QLM3003 vs ZL-82 · baricitinib vs QLM3003 · QLM3003 vs upadacitinib · baricitinib vs ZL-82 · upadacitinib vs ZL-82 · baricitinib vs upadacitinib